Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumulative patient years of exposure in boys affected by Duchenne muscular dystrophy (DMD). These data were presented by Dr. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System, and Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent in DMD at the 24th International Annual Congress of the World Muscle Society.